|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Free/Total** | **Cancer** | **Benign** | **Total** | **% Positive for cancer** |
|  | >0.35 | 4 | 14 | 18 | 22.22 |
|  | 0.35 | 2 | 1 | 3 | 66.67 |
|  | 0.34 | 5 | 1 | 6 | 83.33 |
|  | 0.33 | 0 | 1 | 1 | 0.00 |
|  | 0.32 | 0 | 3 | 3 | 0.00 |
|  | 0.31 | 1 | 2 | 3 | 33.33 |
|  | 0.3 | 1 | 2 | 3 | 33.33 |
|  | 0.29 | 3 | 2 | 5 | 60.00 |
|  | 0.28 | 3 | 5 | 8 | 37.50 |
|  | 0.27 | 5 | 0 | 5 | 100.00 |
|  | 0.26 | 3 | 4 | 7 | 42.86 |
|  | 0.25 | 7 | 13 | 20 | 35.00 |
|  | 0.24 | 8 | 4 | 12 | 66.67 |
|  | 0.23 | 10 | 12 | 22 | 45.45 |
|  | 0.22 | 14 | 16 | 30 | 46.67 |
|  | 0.21 | 11 | 18 | 29 | 37.93 |
|  | 0.2 | 24 | 16 | 40 | 60.00 |
|  | 0.19 | 26 | 16 | 42 | 61.90 |
|  | 0.18 | 23 | 19 | 42 | 54.76 |
|  | 0.17 | 29 | 26 | 55 | 52.73 |
|  | 0.16 | 31 | 33 | 64 | 48.44 |
|  | 0.15 | 41 | 25 | 66 | 62.12 |
|  | 0.14 | 43 | 27 | 70 | 61.43 |
|  | 0.13 | 53 | 30 | 83 | 63.86 |
|  | 0.12 | 58 | 25 | 83 | 69.88 |
|  | 0.11 | 75 | 22 | 97 | 77.32 |
|  | 0.10 | 73 | 16 | 89 | 82.02 |
|  | 0.09. | 81 | 11 | 92 | 88.04 |
|  | 0.08 | 79 | 14 | 93 | 84.95 |
|  | 0.07 | 79 | 3 | 82 | 96.34 |
|  | 0.06 | 76 | 4 | 80 | 95.00 |
|  | 0.05 | 54 | 6 | 60 | 90.00 |
|  | 0.04 | 56 | 6 | 62 | 90.32 |
|  | 0.03 | 19 | 2 | 21 | 90.48 |
|  | 0.02 | 4 | 1 | 5 | 80.00 |
|  |  |  |  |  |  |
| TOTAL |  | 1001 | 400 | 1401 |  |

**NOTES**

1. **Statistics as at 6th November 2019**
2. **Whilst it is difficult to draw any firm conclusions on the ratios 0.26 and above because the numbers are small and therefore subject to significant fluctuation, there is a clear indication for ratios 0.10 and below that the lower the ratio the higher the risk, particularly as sample sizes are reasonable**
3. **This Summary is produced from information supplied by David Baxter Smith M.A, M.Sc, M.B, B.Ch, B.A.O, F.R.C.S Retired Consultant Urologist, an unpaid Adviser to the Charity.**